by andrewmm2007 | Oct 28, 2021 | Press Releases
New investment to fuel continued growth of 3M³ platform for the development of products in tissue reconstruction and oncology Mont Saint-Guibert, Belgium – October 28, 2021 – Novadip Biosciences (“Novadip” or “the Company”), a clinical stage company developing...
by andrewmm2007 | Oct 18, 2021 | Featured News
Novadip SA raised €19 million (US$22.1 million) in a first close of a series B round to progress its autologous bone regeneration therapy, NVD-003, on either side of the Atlantic. The company is also working on an allogeneic regenerative approach, which is still...
by andrewmm2007 | Jun 15, 2021 | Press Releases
Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion. Primary endpoint met, study validates autologous cell therapy 3M³ platform for bone regeneration and demonstrates manufacturing capabilitiesNext generation autologous...
by andrewmm2007 | Mar 4, 2021 | Press Releases
Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003 Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert, Mar 4, 2021 (GlobeNewswire) – Novadip Biosciences (“Novadip”), a...
by andrewmm2007 | Dec 23, 2020 | Press Releases
Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation – Dual designations granted for NVD-003 for the Treatment of Congenital Pseudarthrosis of the Tibia a serious and debilitating condition that primarily affects children...
